Project Leaders

• Dr Andrew Stephens
• Dr Maree Bilandzic
• Professor Ron Firestein
• Professor Paul Hertzog

Precision medicine is poised to revolutionise healthcare, as new indications for existing drugs become more widely applied according to molecular, rather than physiological, parameters. We have initiated a precision medicine program in ovarian cancer, specifically to improve outcomes for patients.

This project will focus on the characterisation of specific drug responses, linked to clinical and molecular information, to drive new therapeutic interventions and functional approaches for patients.